|
TransMolecular's 131I-TM601 Successfully Localizes to Multiple Tumor Types without Targeting Healthy Tissue |
|
|
TransMolecular Presents New Data Highlighting the Anti-angiogenic and Tumor-targeting Properties of TM601 at ASCO Annual Meeting |
|
|
TransMolecular Announces Presentation of Data Highlighting Anti-angiogenic and Tumor-targeting Properties of TM601 at ASCO Annual Meeting |
Our company is committed to discovering, developing and commercializing novel, targeted therapies for cancers with limited treatment options. Our experienced team is dedicated to expediting the research and approval processes necessary to bring promising new treatment options - as well as renewed hope - to millions of patients who need them.
Our lead compound is TM601 (Chlorotoxin), for the treatment of various cancers and opthalmalogic, neo-vascular diseases. A unique tumor targeting compound, TM601 also inhibits the activity of a number of pro-angiogenic pathways, making it a versatile anti-angiogenic agent.